Acasti Pharma Inc  

(Public, CVE:APO)   Watch this stock  
Find more results for APO
0.465
+0.005 (1.09%)
Aug 31 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.46 - 0.47
52 week 0.35 - 1.20
Open 0.47
Vol / Avg. 4,625.00/32,666.00
Mkt cap 49.58M
P/E     -
Div/yield     -
EPS -0.04
Shares 106.62M
Beta 1.47
Inst. own     -
Jul 13, 2015
Q1 2016 Acasti Pharma Inc Earnings Release
  

Key stats and ratios

Q2 (May '15) 2015
Net profit margin -18752.43% -611.46%
Operating margin -50661.94% -4580.02%
EBITD margin - -3717.11%
Return on average assets -10.71% -3.99%
Return on average equity -11.82% -4.98%
CDP Score - -

Address

545 Promenade du Centropolis, Suite 100
LAVAL, QC H7T 0A3
Canada
+1-450-6864555 (Phone)
+1-450-6862505 (Fax)

Website links

Description

Acasti Pharma Inc. is a Canada-based biopharmaceutical company focused on the research, development and commercialization of new krill-oil based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, in particular abnormalities in blood lipids, referred to as dyslipidemia. The Company owns a prescription drug candidate, CaPre, as well as a medical food, Onemia, which is available in the market. The Company is conducted a Phase II open label (COLT) study, the results of, which showed that CaPre was safe and effective in reducing triglycerides in patients with mild to severe hypertriglyceridemia. It is conducting a Phase II double blind (TRIFECTA) trial on CaPre to evaluate the safety and efficacy of CaPre on patients with hypertriglyceridemia. The Company is also conducting a Pharmacokinetics trial on CaPre in collaboration with Quintiles.

Officers and directors

Jerald J. Wenker Independent Chairman of the Board
Pierre Lemieux Ph.D. Chief Operating Officer
Laurent Harvey Vice President- Clinical and Non-Clinical Affairs
Jean Daniel Belanger Secretary, Director- Corporate Affairs
Harlan W. Waksal M.D. Director
Age: 61
Valier Boivin Independent Director
Jean-Claude Debard Independent Director
Ronald Denis Independent Director
Pierre Fitzgibbon Independent Director
Age: 60